(News Bulletin 247) – GSK announces that its HIV company, ViiV Healthcare, yesterday announced positive results over 12 months from a phase IIIb study comparing the 1st and only complete long-acting injectable regimen Cabenuva (cabotegravir, rilpivirine [CAB+RPV LA]) and the Biktarvy complete daily oral regimen (bictegravir/emtricitabine/tenofovir alafenamide [BIC/FTC/TAF]).
Study results showed that CAB+RPV LA administered every two months achieved the primary endpoint of non-inferior virological efficacy compared to BIC/FTC/TAF.
90% of participants who experienced both therapies preferred the long-acting regimen, CAB+RPV LA, and switching from one to the other was “effective and well tolerated”, specifies the laboratory.
Long-acting treatment is indeed more convenient for people with HIV, especially considering that at the start of the study, 47% of participants said they were ‘worried about people unwittingly finding out their HIV status ‘, ‘worrying about forgetting to take their HIV medication,’ or indicated that ‘taking their HIV medication was an uncomfortable reminder of their HIV status’.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
